TW200404534A - Methods of treating dry eye disorders - Google Patents

Methods of treating dry eye disorders Download PDF

Info

Publication number
TW200404534A
TW200404534A TW092124459A TW92124459A TW200404534A TW 200404534 A TW200404534 A TW 200404534A TW 092124459 A TW092124459 A TW 092124459A TW 92124459 A TW92124459 A TW 92124459A TW 200404534 A TW200404534 A TW 200404534A
Authority
TW
Taiwan
Prior art keywords
dry eye
inhibitor
patent application
inhibitors
composition
Prior art date
Application number
TW092124459A
Other languages
English (en)
Chinese (zh)
Inventor
Daniel A Gamache
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of TW200404534A publication Critical patent/TW200404534A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW092124459A 2002-09-20 2003-09-04 Methods of treating dry eye disorders TW200404534A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41246302P 2002-09-20 2002-09-20

Publications (1)

Publication Number Publication Date
TW200404534A true TW200404534A (en) 2004-04-01

Family

ID=32030872

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092124459A TW200404534A (en) 2002-09-20 2003-09-04 Methods of treating dry eye disorders

Country Status (14)

Country Link
US (2) US7026296B2 (enExample)
EP (1) EP1542768A1 (enExample)
JP (1) JP2006502183A (enExample)
KR (1) KR20050057175A (enExample)
CN (1) CN1684738A (enExample)
AR (1) AR041262A1 (enExample)
AU (1) AU2003278727A1 (enExample)
BR (1) BR0314603A (enExample)
CA (1) CA2497977A1 (enExample)
MX (1) MXPA05003063A (enExample)
PL (1) PL374700A1 (enExample)
TW (1) TW200404534A (enExample)
WO (1) WO2004026406A1 (enExample)
ZA (1) ZA200502119B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
RU2005118425A (ru) * 2002-11-15 2006-02-10 Сэнгстат Медикал Корпорейшн (Us) Цитомодуляторные пептиды для лечения интерстициального цистита
US7235556B2 (en) 2003-04-16 2007-06-26 Alcon, Inc. Methods of treating dry eye disorders
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
AU2004294343A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ICE inhibitors
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
CN101175488B (zh) 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR20080021782A (ko) * 2005-06-17 2008-03-07 리지너크스 바이오 파마소티컬스, 인코포레이티드 엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들 및 그 방법
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
JP2007133001A (ja) * 2005-11-08 2007-05-31 Seed Co Ltd コンタクトレンズ用ケア用剤
ATE525374T1 (de) 2005-12-13 2011-10-15 Incyte Corp Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
EP3167886B1 (en) 2007-10-19 2020-08-05 Novartis AG Compositions and methods for treatment of macular edema
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
JP6172939B2 (ja) 2009-05-22 2017-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
KR102303885B1 (ko) 2010-05-21 2021-09-24 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
SG11201402347YA (en) * 2011-11-30 2014-06-27 Xigen Inflammation Ltd Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
HK1210782A1 (en) 2012-07-25 2016-05-06 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
TR201820520T4 (tr) 2013-03-06 2019-01-21 Incyte Holdings Corp Bir jak inhibitörü yapmaya yönelik prosesler ve ara ürünler.
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
DK3030227T3 (da) 2013-08-07 2020-04-20 Incyte Corp Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
EP3069732B1 (en) * 2013-11-14 2023-07-12 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
WO2017066758A1 (en) * 2015-10-15 2017-04-20 The Schepens Eye Research Institute, Inc. P38 map kinase inhibitors for wound healing
CN105496955A (zh) * 2015-12-11 2016-04-20 北京蓝丹医药科技有限公司 一种二氟泼尼酯眼用乳剂及其制备方法
WO2017110093A1 (ja) 2015-12-24 2017-06-29 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
MA56215A (fr) 2019-06-10 2022-04-20 Incyte Corp Traitement topique du vitiligo par un inhibiteur de jak
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20250073194A1 (en) * 2022-02-01 2025-03-06 Baylor College Of Medicine Rxr agonists in eye disorders

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5712298A (en) 1993-07-02 1998-01-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6043083A (en) * 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
JPH10330257A (ja) 1997-06-02 1998-12-15 Senju Pharmaceut Co Ltd 眼局所用サイトカイン産生抑制剤
US5980929A (en) * 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
ES2136581B1 (es) 1998-05-27 2000-09-16 Uriach & Cia Sa J Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
JP2002520355A (ja) * 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド 非アレルギー性眼炎症障害を処置および眼新生血管形成を予防する医薬製造のための、１１−（３−ジメチルアミノプロピリデン）−６，１１−ジヒドロジベンズ［ｂ，ｅ］オキセピン−２−酢酸の使用
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
ES2242643T3 (es) 1999-11-09 2005-11-16 Alcon Inc. Sales de hidroxieicosatetraenoato, composiciones y metodos de uso en el tratamiento de trastornos del ojo seco.
KR20020050237A (ko) 1999-11-09 2002-06-26 구이도 콜러, 스테판 바슬러 오메가 체인이 변형된 15-하이드록시에이코사테트라엔산유도체 및 안구 건조증의 치료를 위한 그들의 사용방법
JP2003513950A (ja) 1999-11-09 2003-04-15 アルコン，インコーポレイテッド １５−ヒドロキシエイコサテトラエン酸のベンゼノイド誘導体およびドライアイ障害を処理するのに使用する方法
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
ATE257143T1 (de) 1999-11-09 2004-01-15 Alcon Inc 15-hydroxyeicosatetraensäure verwandte verbindungen und anwendungsverfahren
EP1228032B1 (en) 1999-11-09 2004-08-04 Alcon Inc. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
AU1226001A (en) 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
EP1227809B1 (en) 1999-11-09 2005-04-06 Alcon Inc. Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
WO2001034553A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
AU776146B2 (en) 1999-11-09 2004-08-26 Alcon Inc. 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
US6320062B1 (en) 1999-11-09 2001-11-20 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
NZ519222A (en) 1999-12-14 2004-04-30 Genentech Inc TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
AU2001288271A1 (en) 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
US20020151491A1 (en) 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
US20020132823A1 (en) * 2001-01-17 2002-09-19 Jiahuai Han Assay method
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
ATE333273T1 (de) 2001-05-21 2006-08-15 Alcon Inc Verwendung von nf-kappa.b inhibitoren zur behandlung von augentrockenheit
NZ537308A (en) 2002-05-28 2009-09-25 Nycomed Gmbh Ophthalmological use of roflumilast for the treatment of diseases of the eye
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders

Also Published As

Publication number Publication date
CN1684738A (zh) 2005-10-19
PL374700A1 (pl) 2005-10-31
BR0314603A (pt) 2005-07-26
WO2004026406A1 (en) 2004-04-01
US7026296B2 (en) 2006-04-11
ZA200502119B (en) 2006-09-27
US20060189541A1 (en) 2006-08-24
EP1542768A1 (en) 2005-06-22
CA2497977A1 (en) 2004-04-01
JP2006502183A (ja) 2006-01-19
US20040058875A1 (en) 2004-03-25
KR20050057175A (ko) 2005-06-16
AR041262A1 (es) 2005-05-11
MXPA05003063A (es) 2005-05-27
AU2003278727A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
TW200404534A (en) Methods of treating dry eye disorders
WO2001041806A1 (en) Ophthalmic compositions
JP2001500964A (ja) 合成甲状腺ホルモン組成物を使用した眼の処置
JPH09507065A (ja) 高眼内圧の治療への非ステロイド系シクロオキシゲナーゼ阻害剤の使用
JPS6038323A (ja) 眼科用消炎剤
CN111867560A (zh) 包含噻吗洛尔的药物组合物
WO2007058935A2 (en) Ophthalmic composition for dry eye therapy
JP2000506833A (ja) 斑水腫の治療
WO2009052140A1 (en) Use of tnf receptor antagonists for treating dry eye
US6645994B1 (en) Method of treating dry eye disorders
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
CN109528628B (zh) 一种包含左卡尼汀的药用组合物及其制备方法和用途
AU2002309963B2 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
JP2023038930A (ja) 眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法
JPS5929616A (ja) 抗炎症眼科用液剤およびその製法
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
TW200536517A (en) Compositions of a phenyl acetic acid cyclooxygenase-2 selective inhibitor for the treatment of cyclooxygenase-2 mediated ocular disorders
JP3496111B2 (ja) 涙液分泌促進および角結膜障害治療剤
CN117618333A (zh) 一种更昔洛韦眼用制剂及其制备方法
CN115645420A (zh) 甘露糖及其药用衍生物在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用
US20040209888A1 (en) Methods of treating dry eye disorders
CA2255202A1 (fr) Utilisation de la flavine-adenine-dinucleotide pour la preparation de compositions ophtalmiques utiles pour le traitement de l'oeil sec
JP2000336042A (ja) 眼圧下降剤